Use of antibiotics during pregnancy

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 81, Issue 1, 1998, Pages 1-8

  Czeizel, Andrew E ^a   Rockenbauer, Magda ^a   Olsen, Jorn ^a  

^a NONE

Author keywords

Antibiotic use during pregnancy; Higher birth weight; Risk benefit estimation; Underlying maternal disorders

Indexed keywords

AMPICILLIN; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; OXYTETRACYCLINE; PENAMECILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PROCAINE PENICILLIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; BIRTH WEIGHT; CONGENITAL DISORDER; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; HUNGARY; PREGNANCY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0032189523     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00138-9     Document Type: Article

References (20)

1. [1] Shepard TH. Catalog of Teratogenic Agents. 7th ed. Baltimore: Johns Hopkins University Press, 1992.
2. [2] Taylor D, Tarnow-Mordi W. Infection and preterm labour. Br J Obstet Gynaecol 1997;104:1338-40.
3. [3] Czeizel AE. Analysis of medical indications for induced abortions (Hungarian with English abstract). Orvosi Hetilap 1983;124:1297-302.
4. [4] Czeizel AE, Rácz J. Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology 1990;42:505-12.
5. [5] Czeizel AE. First 25 years of the Hungarian Congenital Abnormality Registry. Teratology 1997;55:299-305.
6. [6] Garau J. β-lactamases: current situation and clinical importance. Intens Care Med 1994;20(Suppl. 3):65-9.
7. [7] Parry MF. The penicillins. Med Clin N Am 1987;71:1093-112.
8. [8] Gilbert DN. Aminoglycosides. In: Principles and practice of infectious diseases. Churchill Livingstone. 1995:279-300.
9. [9] Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
10. [10] Reese RE, Betts RF, Douglas RG. The tetracyclines. A practical approach to infectious diseases. Boston: Little Brown, 3rd ed. 1991:968-974.
11. [11] Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Arch Gynec Obstet, in press.
12. [12] Czeizel AE, Rockenbauer M. Teratogenic study of doxycycline. Obstet Gynecol 1997;89:524-8.
13. [13] The Pharmaceutical Market World Review 1990-1996.
14. [14] Gibbs RS, Romero R, Hillier SL, et al. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992;166:1514-28.
15. [15] Owen J, Groome LJ, Hauth JC. Randomised trial of prophylactic antibiotic therapy after preterm rupture. Am J Obstet Gynecol 1993;169:976-81.
16. [16] Mercer BM, Miodornik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. J Am Med Assoc 1997;278:989-95.
17. [17] Goldstein I, Romero R, Merrill S, et al. Fetal body and breathing movement as predictors of intraamniotic infection in preterm premature rupture of membranes. Am J Obstet Gynecol 1988;159:363-8.
18. [18] Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. J Am Med Assoc 1997;278:207-11.
19. [19] Czeizel AE. Recommendations to avoid all drugs during first trimester is unrealistic. Br Med J 1996;313:424-5.
20. [20] Czeizel AE. Primary prevention of birth defects by periconceptional care, including multivitamin supplementation. Balliére's Clin Obstet Gynecol 1995;9(3):417-30.